Daniel H. Ahn, DO

Daniel H. Ahn, DO, discusses research surrounding the combination of atebimetinib and modified gemcitabine and nab-paclitaxel (Abraxane) in pancreatic cancer.

Choosing between triplet and doublet regimens requires careful individualization based on performance status, comorbidities, and disease burden. This segment examines the clinical factors guiding selection between NALIRIFOX and FOLFIRINOX, including peripheral neuropathy risk, GI tolerability, and the role of genomic mutations in sensitizing tumors to platinum-based or DNA-damaging agents.

The first-line treatment landscape for metastatic pancreatic ductal adenocarcinoma (mPDAC) has evolved significantly, yet options remain limited for this challenging disease. This opening segment explores how performance status, age, frailty, molecular profiling, and patient preferences drive treatment selection.

Dr. Saeed summarizes the principal clinical lessons from STELLAR 303 and their implications for the management of refractory MSS metastatic colorectal cancer.

Dr. Saeed describes the rationale and design of STELLAR 316, a three-arm phase 3 trial evaluating zanzalintinib-based therapy in patients with stage III MSS colorectal cancer who test positive for circulating tumor DNA following surgery and adjuvant chemotherapy.

Dr. Saeed and Dr. Ahn address how zanzalintinib plus atezolizumab fits alongside the expanding array of biomarker-targeted therapies in metastatic colorectal cancer.

Dr. Saeed and Dr. Ahn examine the safety data from STELLAR 303 and discuss practical strategies for managing toxicity in clinical practice.

Dr. Saeed presents the design and primary efficacy results of STELLAR 303, the phase 3 trial evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with chemorefractory MSS metastatic colorectal cancer.

Dr. Saeed and Dr. Ahn review what has been learned from early phase trials examining multi-kinase inhibitors combined with immune checkpoint inhibitors in MSS metastatic colorectal cancer, including LEAP-017 and COSMIC-021.

Dr. Saeed and Dr. Ahn discuss the biologic features that make non-MSI-high colorectal cancer resistant to immune checkpoint inhibition and the scientific rationale for combining multi-kinase inhibitors with immunotherapy.

Anwaar Saeed, MD, and Daniel Ahn, MD, open this OncLive Insights program with an overview of the current treatment landscape for patients with non-MSI-high metastatic colorectal cancer who have progressed on standard chemotherapy, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the increased understanding of cholangiocarcinoma.

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses considerations for treatment with atezolizumab and bevacizumab in patients with hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Daniel H. Ahn, DO, discusses ​updated findings from the ​phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Daniel H. Ahn, DO, discusses advancing actionable alterations in colorectal cancer.

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.

Daniel H. Ahn, DO, internist, Mayo Clinic, discusses advances in neoadjuvant therapies for patients with gastric cancer during the 2017 OncLive State of the Science Summit on Gastrointestinal Malignancies.